Crown BioScience NAFLD model in development

Crown BioScience recently reported that it is currently developing a non-alcoholic fatty liver disease (NAFLD) model.

"The new model complements our NHP model of NAFLD and non-alcoholic steatohepatitis (NASH), creating a continuum of in vivo platforms that enables us to provide our clients with end-to-end preclinical support for their CVMD research," CrownBio SVP of Cardiovascular and Metabolic disease Dr. Jim Wang said. "It can be used as a translational tool to study novel compounds in late stage drug discovery."

Created by Crown Bioscience subsidiary PreClinOmics, which specializes in metabolic, cardiovascular and renal disease preclinical contract services, the NAFLD model was produced using PreClinOmics’ obesity and Type 2 diabetes FATZO model. The spontaneously hyperglycemic FATZO model has served as a translational platform for the development of NAFLD models.

There no currently approved therapies for NASH, PreClinOmics General Manager and CSO Van Jackson said.

"In its most severe form, NASH disease can lead to liver cancer and the need for transplantation," he said. "We are hopeful this new research model can be used as a translational model for NASH and lead to new avenues for treatment and recovery."